Munich, Germany \u2014 smart\u00adbax, a biotech company deve\u00adlo\u00adping next-gene\u00adra\u00adtion anti\u00adbio\u00adtics, announ\u00adced the closing of a \u20ac1.2 million seed finan\u00adcing round with Boeh\u00adrin\u00adger Ingel\u00adheim Venture Fund (BIVF) and High-Tech Gr\u00fcn\u00adder\u00adfonds (HTGF). Thus, smart\u00adbax has so far raised a total of 1.9 million euros for the deve\u00adlo\u00adp\u00adment of inno\u00adva\u00adtive anti\u00adbio\u00adtics against multi-resistant bacteria.<\/p>\n
With the new capi\u00adtal, the company will advance its precli\u00adni\u00adcal small mole\u00adcule anti\u00adbio\u00adtic disco\u00advery studies and expand its scien\u00adti\u00adfic team to further deve\u00adlop its inno\u00adva\u00adtive rese\u00adarch plat\u00adforms and find new solu\u00adti\u00adons against multi-drug resistant patho\u00adgens. Unlike clas\u00adsi\u00adcal anti-bacte\u00adrial agents, smart\u00adbax\u2019s product candi\u00adda\u00adtes act via a unique, dual-targe\u00adting mecha\u00adnism. This not only inhi\u00adbits essen\u00adtial proces\u00adses in the energy meta\u00adbo\u00adlism of the multi-resistant bacte\u00adria, but also crea\u00adtes a stimu\u00adla\u00adtion of the protein secre\u00adtion of the bacte\u00adria, which leads to the self-diges\u00adtion of the cells.<\/p>\n
\u201cThe growing number of multid\u00adrug-resistant infec\u00adtions, which alre\u00adady account for 1.3 million deaths world\u00adwide each year, high\u00adlights the urgent need for new approa\u00adches to treat resistant infec\u00adtions. We are convin\u00adced that with our diffe\u00adren\u00adtia\u00adted approach we can over\u00adcome the limi\u00adta\u00adti\u00adons of curr\u00adently available anti\u00adbio\u00adtics and thus deve\u00adlop effec\u00adtive thera\u00adpeu\u00adtics against both Gram-posi\u00adtive and Gram-nega\u00adtive bacte\u00adria,\u201d said Dr. Robert Macsics, CEO and co-foun\u00adder of smart\u00adbax<\/strong>.<\/p>\n smart\u00adbax was foun\u00added in 2021 by Dr. Robert Macsics, Marco Jane\u00adzic and Prof. Dr. Stephan Sieber and supported by initial start-up funding of 700,000 euros from the BIVF. The company\u2019s scien\u00adti\u00adfic foun\u00adda\u00adti\u00adons are based on outstan\u00adding rese\u00adarch results from Prof. Dr. Sieber\u2019s working group at the Tech\u00adni\u00adcal Univer\u00adsity of Munich (TUM). These have alre\u00adady recei\u00adved the VIP+ Vali\u00adda\u00adtion Award from the German Fede\u00adral Minis\u00adtry of Educa\u00adtion and Rese\u00adarch and the m4 Award from the Bava\u00adrian State Minis\u00adtry of Econo\u00admic Affairs, Regio\u00adnal Deve\u00adlo\u00adp\u00adment and Energy.<\/p>\n \u201cThe inno\u00adva\u00adtive mecha\u00adnisms of action explo\u00adred by smart\u00adbax may open new avenues in the fight against serious bacte\u00adrial infec\u00adtions. The approach also appears promi\u00adsing to over\u00adcome exis\u00adting resis\u00adtance mecha\u00adnisms and makes rapid spread of new resis\u00adtance unli\u00adkely. I am plea\u00adsed that we can accom\u00adpany the scien\u00adti\u00adfi\u00adcally strong team of smart\u00adbax on their way to meet a highly rele\u00advant socie\u00adtal chall\u00adenge\u201d, explains Dr. Ange\u00adlika Vlachou, Part\u00adner at HTGF.<\/p>\n \u201cThe deve\u00adlo\u00adp\u00adment of novel anti\u00adbio\u00adtics repres\u00adents a valuable contri\u00adbu\u00adtion to the fight against multid\u00adrug-resistant bacte\u00adrial infec\u00adtions. The foun\u00adding team of smart\u00adbax is pursuing a highly inno\u00adva\u00adtive approach, which offers the poten\u00adtial for broad appli\u00adca\u00adbi\u00adlity in nume\u00adrous dise\u00ada\u00adses. We are plea\u00adsed to accom\u00adpany smart\u00adbax in its further rese\u00adarch acti\u00advi\u00adties and ther\u00adeby support the deve\u00adlo\u00adp\u00adment of new and urgen\u00adtly needed thera\u00adpeu\u00adtic approa\u00adches in the field of bacte\u00adrial infec\u00adtious dise\u00ada\u00adses,\u201d says Dr. Sebas\u00adtian Kreuz, Invest\u00adment Mana\u00adger of the BIVF.<\/p>\n About smart\u00adbax About the Boeh\u00adrin\u00adger Ingel\u00adheim Venture Fund The BIVF takes an active role within its port\u00adfo\u00adlio compa\u00adnies \u2014 deli\u00adve\u00adring signi\u00adfi\u00adcant added value through its own scien\u00adti\u00adfic and busi\u00adness exper\u00adtise in drug deve\u00adlo\u00adp\u00adment. The BIVF has a volume of EUR 300 million, is repre\u00adsen\u00adted by offices in Europe (Germany), the USA (Boston and San Fran\u00adcisco) and China (Beijing and Hong Kong) and curr\u00adently over\u00adlooks a port\u00adfo\u00adlio of 40 companies. About High-Tech Gr\u00fcnderfonds The fund inves\u00adtors in the public-private part\u00adner\u00adship include the German Fede\u00adral Minis\u00adtry for Econo\u00admic Affairs and Climate Protec\u00adtion, KfW Capi\u00adtal, the Fraun\u00adho\u00adfer-Gesell\u00adschaft and over 40 compa\u00adnies from a wide range of industries.<\/p>\n Advi\u00adsors to Boeh\u00adrin\u00adger Ingel\u00adheim Venture Fund (BIVF) and High-Tech Gr\u00fcn\u00adder\u00adfonds (HTGF): Green\u00adGate Part\u00adners<\/strong> provi\u00added compre\u00adhen\u00adsive support to the two funds in struc\u00adtu\u00adring and imple\u00admen\u00adting the finan\u00adcing round as well as in draf\u00adting and nego\u00adtia\u00adting the rele\u00advant contrac\u00adtual documents.<\/p>\n <\/p>\n","protected":false},"excerpt":{"rendered":" Munich, Germany \u2014 smart\u00adbax, a biotech company deve\u00adlo\u00adping next-gene\u00adra\u00ad\u00adtion anti\u00adbio\u00adtics, announ\u00adced the closing of a \u20ac1.2 million seed finan\u00adcing round with Boeh\u00adrin\u00adger Ingel\u00adheim Venture Fund (BIVF) and High-Tech Gr\u00fcn\u00adder\u00adfonds (HTGF). Thus, smart\u00adbax has so far raised a total of 1.9 million euros for the deve\u00adlo\u00adp\u00adment of inno\u00adva\u00adtive anti\u00adbio\u00adtics against multi-resistant bacte\u00adria. With the new capital, [\u2026]<\/p>\n","protected":false},"author":2,"featured_media":48604,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"wp_typography_post_enhancements_disabled":false,"footnotes":""},"categories":[886,1364,1366,1373],"tags":[],"class_list":["post-48612","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-general-en","category-featured-en","category-news-en","category-venture-capital-en"],"yoast_head":"\n
\n<\/strong>
\nsmart\u00adbax is deve\u00adlo\u00adping a new gene\u00adra\u00adtion of anti\u00adbac\u00adte\u00adrial agents to combat the incre\u00adasing spread of multi-resistant bacte\u00adria. The team of experts is rely\u00ading on inno\u00adva\u00adtive solu\u00adti\u00adons that attack bacte\u00adria at diffe\u00adrent sites simul\u00adta\u00adneously, thus making it more diffi\u00adcult for resis\u00adtance to form. In addi\u00adtion, the company specia\u00adli\u00adzes in the targe\u00adted acti\u00adva\u00adtion of enzy\u00adma\u00adtic proces\u00adses in bacte\u00adria, which is a parti\u00adcu\u00adlarly promi\u00adsing approach in the context of biofilms that are diffi\u00adcult to treat. Knowing that tomor\u00adro\u00adw\u2019s resis\u00adtance crisis can only be aver\u00adted by acting today, smart\u00adbax 2021 was foun\u00added in Munich with the goal of making inno\u00adva\u00adtive rese\u00adarch appli\u00adca\u00adble to create novel anti\u00adbio\u00adtics that add real value to pati\u00adents worldwide.
\nWebsite link: https:\/\/www.smartbax.de<\/p>\n
\n<\/strong>
\nSince its incep\u00adtion in 2010, Boeh\u00adrin\u00adger Ingel\u00adheim Venture Fund GmbH (BIVF) has been inves\u00adt\u00ading in breakth\u00adrough biotech\u00adno\u00adlogy compa\u00adnies in the thera\u00adpeu\u00adtics field to foster inno\u00adva\u00adtion in biome\u00addi\u00adcal rese\u00adarch. The BIVF seeks signi\u00adfi\u00adcant impro\u00adve\u00adments in pati\u00adent care through scien\u00adti\u00adfic pionee\u00adring and its clini\u00adcal appli\u00adca\u00adtion by buil\u00adding long-term rela\u00adti\u00adonships with scien\u00adtists and entre\u00adpre\u00adneurs. The BIVF focu\u00adses on novel thera\u00adpeu\u00adtic concepts charac\u00adte\u00adri\u00adzed by high unmet medi\u00adcal need in the fields of immuno-onco\u00adlogy, rege\u00adne\u00adra\u00adtive medi\u00adcine, multi-resistant bacte\u00adrial infec\u00adtions and digi\u00adtal health. This includes new plat\u00adform tech\u00adno\u00adlo\u00adgies that address previously unad\u00addressa\u00adble targets and new biolo\u00adgi\u00adcal entities.<\/p>\n
\nwww.boehringer-ingelheim-venture.com<\/p>\n
\n<\/strong>
\nThe seed inves\u00adtor High-Tech Gr\u00fcn\u00adder\u00adfonds (HTGF) finan\u00adces tech\u00adno\u00adlogy start-ups with growth poten\u00adtial and has supported more than 700 start-ups since 2005. With the launch of the fourth fund, HTGF has around 1.4 billion euros under manage\u00adment. The team of expe\u00adri\u00aden\u00adced invest\u00adment mana\u00adgers and start-up experts supports the young compa\u00adnies with know-how, entre\u00adpre\u00adneu\u00adrial spirit and passion. The focus is on high-tech start-ups in the fields of digi\u00adtal tech, indus\u00adtrial tech, life scien\u00adces, chemis\u00adtry and rela\u00adted busi\u00adness areas. More than \u20ac4.5 billion in capi\u00adtal has been inves\u00adted in the HTGF port\u00adfo\u00adlio by exter\u00adnal inves\u00adtors in more than 2,000 follow-on finan\u00adcing rounds to date. In addi\u00adtion, the fund has alre\u00adady successfully sold shares in more than 170 companies.<\/p>\n